RTOG 0848: A Phase III Trial Evaluating both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Description of Research
This study will compare the effects, good and/or bad, of the drug erlotinib in combination with gemcitabine to gemcitabine alone for patients with pancreatic cancer that was removed by surgery to find out which is better. Erlotinib is a pill that may help treat cancers by blocking a gene that is important in cancer growth. Erlotinib, also known as Tarceva®, is approved by the FDA when taken in combination with gemcitabine for the treatment of pancreatic cancer that has spread and cannot be removed by surgery. The use of erlotinib to try to prevent the recurrence of pancreatic cancer after surgery is considered investigational. This study will also determine the effects, good and/or bad, of radiation for patients who remain disease-free after gemcitabine chemotherapy.
Jedidiah Monson, M.D.
Resected head of pancreas adenocarcinoma. This includes the pancreatic head, uncinate process, and neck of the pancreas, status post a curative-intent pancreaticoduodenectomy